Table 1.
Characteristic | Benzodiazepine within 6 mo, n=11,289 | No Benzodiazepine within 6 mo, n=58,079 |
---|---|---|
Age, yr, median [IQR] | 68 [59–77] | 67 [56–76] |
BMI, kg/m2, median [IQR] | 28 [24–34] | 28 [24–34] |
Women, % | 54 | 44 |
White, % | 80 | 65 |
Dialysis initiation in 2013, % | 59 | 57 |
Opioids, % | 76 | 56 |
Neuropathic pain medication, % | ||
Any | 68 | 49 |
Gabapentin | 26 | 18 |
Antidepressant, % | 56 | 29 |
CNS depressant, % | 37 | 18 |
Comorbidity, % | ||
Diabetes | 58 | 60 |
Cardiovascular disease | 57 | 52 |
Peripheral vascular disease | 14 | 11 |
Hypertension | 88 | 89 |
COPD | 16 | 10 |
Tobacco use | 8 | 6 |
Cancer | 8 | 7 |
Drug use | 3 | 2 |
Inability to ambulate | 20 | 16 |
Institutionalized | 13 | 9 |
No comorbidity | 1 | 2 |
Cause of kidney failure, % | ||
Diabetes | 47 | 49 |
Hypertensive kidney disease | 31 | 32 |
GN | 6 | 6 |
Other | 16 | 13 |
Dual eligible, % | 47 | 46 |
Employment status, % | ||
Unemployed | 19 | 26 |
Full time | 1 | 2 |
Part time | 1 | 2 |
Retired | 46 | 42 |
Disabled | 29 | 24 |
Other | 3 | 4 |
Medications were ascertained at any point during follow-up. IQR, interquartile range; BMI, body mass index; CNS, central nervous system; COPD, chronic obstructive pulmonary disease.